---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-091613"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T13:17:03.150582+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Crinetics to present 8 abstracts at ENDO 2025, including long-term paltusotine data and Phase 2 CAH results

## Summary
- Eight abstracts at ENDO 2025 (July 12-15, San Francisco) covering PALSONIFY (paltusotine), atumelnant, and CRN12755.
- Oral presentation of long-term PATHFNDR-1 open-label extension data for paltusotine in acromegaly, showing durable biochemical and symptom control.
- Phase 2 open-label trial results for atumelnant in congenital adrenal hyperplasia featured as oral presentation; data on adrenal volume and androgen reductions.
- Early-stage pipeline data on CRN12755, a TSHR antagonist for Graves' hyperthyroidism and orbitopathy, also to be presented.
- PALSONIFY conditionally approved as trade name by FDA; atumelnant Phase 2 interim results show rapid reductions in androstenedione and 17-hydroxyprogesterone.

## SEC filing metadata
- accession: 0000950170-25-091613
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017025091613/0000950170-25-091613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017025091613/crnx-20250630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-091613
- JSON: https://secwatch.observer/filing/0000950170-25-091613.json
- Plain text: https://secwatch.observer/filing/0000950170-25-091613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.